MiR-20a-5p promotes radio-resistance by targeting NPAS2 in nasopharyngeal cancer cells

被引:23
|
作者
Zhao, Fangfang [1 ]
Pu, Youguang [1 ]
Qian, Liting [2 ]
Zang, Chunbao [3 ]
Tao, Zhenchao [3 ]
Gao, Jin [2 ]
机构
[1] Anhui Med Univ, Inst Canc Res, Anhui Canc Hosp, West Branch,Anhui Prov Hosp, Hefei 230031, Anhui, Peoples R China
[2] Anhui Med Univ, Anhui Prov Hosp, Dept Radiat Oncol, Hefei 230031, Anhui, Peoples R China
[3] Anhui Med Univ, Anhui Canc Hosp, West Branch, Dept Radiat Oncol,Anhui Prov Hosp, Hefei 230031, Anhui, Peoples R China
关键词
nasopharyngeal cancer; miR-20a-5p; NPAS2; radio-resistance; STEREOTACTIC BODY RADIOTHERAPY; CIRCADIAN GENE NPAS2; HEPATOCELLULAR-CARCINOMA; REGULATES AUTOPHAGY; RADIORESISTANCE; EXPRESSION; GROWTH; PROLIFERATION; NOTCH1; TUMORS;
D O I
10.18632/oncotarget.22411
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) are key players of gene expression involved in diverse biological processes including the cancer radio-resistance, which hinders the effective cancer therapy. Here we found that the miR-20a-5p level is significantly up-regulated in radio-resistant nasopharyngeal cancer (NPC) cells via an RNA-seq and miR-omic analysis. Moreover, we identified that the neuronal PAS domain protein 2 (NPAS2) gene is one of the targets of miR-20a-5p. The involvement of miR-20a-5p and NPAS2 with NPC radio-resistance was further validated by either down-or up-regulation of their levels in NPC cell lines. Taken together, these results not only reveal novel insights into the NPC radio-resistance, but also provide hints for an effective therapeutic strategy to fight against NPC radio-resistance.
引用
收藏
页码:105873 / 105881
页数:9
相关论文
共 50 条
  • [1] MiR-20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells
    Huang, Dabing
    Bian, Geng
    Pan, Yueyin
    Han, Xinghua
    Sun, Yubei
    Wang, Yong
    Shen, Guodong
    Cheng, Min
    Fang, Xiang
    Hu, Shilian
    CANCER CELL INTERNATIONAL, 2017, 17
  • [2] MiR–20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells
    Dabing Huang
    Geng Bian
    Yueyin Pan
    Xinghua Han
    Yubei Sun
    Yong Wang
    Guodong Shen
    Min Cheng
    Xiang Fang
    Shilian Hu
    Cancer Cell International, 17
  • [3] miR-193a-3p Promotes Radio-Resistance of Nasopharyngeal Cancer Cells by Targeting SRSF2 Gene and Hypoxia Signaling Pathway
    Kong, Lingsuo
    Wei, Qing
    Hu, Xianwen
    Chen, Lanren
    Li, Juan
    MEDICAL SCIENCE MONITOR BASIC RESEARCH, 2019, 25 : 53 - 62
  • [4] miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1
    He, Ying
    Ma, Hui
    Wang, Jing
    Kang, Yanhua
    Xue, Qianlong
    ONCOLOGY LETTERS, 2021, 21 (05)
  • [5] Regulatory mechanism of miR-20a-5p expression in Cancer
    Wei Huang
    Xiaoyue Wu
    Shuaixi Xiang
    Mingxin Qiao
    Xiao Cen
    Xuefeng Pan
    Xinqi Huang
    Zhihe Zhao
    Cell Death Discovery, 8
  • [6] Regulatory mechanism of miR-20a-5p expression in Cancer
    Huang, Wei
    Wu, Xiaoyue
    Xiang, Shuaixi
    Qiao, Mingxin
    Cen, Xiao
    Pan, Xuefeng
    Huang, Xinqi
    Zhao, Zhihe
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [7] MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene
    Zhao, Fangfang
    Pu, Youguang
    Cui, Mingda
    Wang, Haiyan
    Cai, Shanbao
    CANCER CELL INTERNATIONAL, 2017, 17
  • [8] MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene
    Fangfang Zhao
    Youguang Pu
    Mingda Cui
    Haiyan Wang
    Shanbao Cai
    Cancer Cell International, 17
  • [9] Paper Long non-coding RNA FAM133B-2 represses the radio-resistance of nasopharyngeal cancer cells by targeting miR-34a-5p/CDK6 axis
    Huang, Dabing
    Zhu, Xianhai
    Wang, Yong
    Yu, Haobin
    Pu, Youguang
    AGING-US, 2020, 12 (17): : 16936 - 16950
  • [10] Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1
    Guo, Ling
    Zhu, Ye
    Li, Liandi
    Zhou, Shufen
    Yin, Guohua
    Yu, Guanghao
    Cui, Hujun
    CANCER MEDICINE, 2019, 8 (12): : 5687 - 5701